Notice: Undefined index: lng_code in /home/spartakhadjiev/www/root/ui_mainfile.php on line 19
"KATRAPS" - The anticancer therapy in patients with malignancies

    Notice: Undefined index: submenu in /home/spartakhadjiev/www/root/templates/system/UI/main.html on line 53
  • Home
  • Application

  • Notice: Undefined index: submenu in /home/spartakhadjiev/www/root/templates/system/UI/main.html on line 53
  • Examples

  • Notice: Undefined index: submenu in /home/spartakhadjiev/www/root/templates/system/UI/main.html on line 53
  • CV

  • Notice: Undefined index: submenu in /home/spartakhadjiev/www/root/templates/system/UI/main.html on line 53
  • Contacts

  • Notice: Undefined index: submenu in /home/spartakhadjiev/www/root/templates/system/UI/main.html on line 53
  • PATENTS

  • Notice: Undefined index: submenu in /home/spartakhadjiev/www/root/templates/system/UI/main.html on line 53
  • Foundation

THE ANTICANCER DRUG "KATRAPS"

 

RULES FOR TREATMENT WITH KATRAPSTM:

 

1.      KATRAPS IS NOT ADMINISTERED DURING CHEMOTHERAPY !

2.      KATRAPS IS NOT ADMINISTERED DURING RADIOTHERAPY !

3.      KATRAPS IS NOT ADMINISTERED TO IMMOBILIZED PATIENTS !

4.      KATRAPS IS NOT ADMINISTERED TO TERMINALLY ILL PATIENTS !

 

DRUG DESCRIPTION

For more than 30 years the drug "KATRAPS" (formerly known as "HD88") has been applied to thousands of patients with different types of cancer. Very good results shown by HD88 permit this drug to be recommended for treatment of cancer (neoplasms).

 

"KATRAPS" is applied strictly intredermally 0.1ml on the volar side of the forearm, like Mantoux. The treatment follows certain therapeutic scheme on time intervals of one to several months.

 

The medicine reaches satisfactory concentrations in the patient’s body generally after the second/third injection and this is the period after which one can expect the curative effect of "KATRAPS": decrease in the concomitant symptoms and after some more injections - regression of the cancer cells. These effects are long-lasting and durable – for months and years.

 

 

AMONG THE MAIN ADVANTAGES OF "KATRAPS" ARE:

1. Powerful immunostimulating effect

2. High effectiveness against different types of neoplasms.

3. High effectiveness against the cancer metastases.

4. Harmless and safety

5. No side effects have been observed

 

"KATRAPS" has proven anticancer activity and showed to be effective in many types of solid neoplasms (tumors) – carcinomas, sarcomas, mesotheliomas, germinomas and gliomas.

 

The effect of "KATRAPS" is expressed in stopping the tumor growth, decreasing the size of the tumor and/or metastases up to their disappearing.

 

 

BEST RESULTS HAVE BEEN OBSERVED WITH:

• Breast cancer
• Cancer of the large bowel (colon & rectum)
• Lung cancer
• Cancer of the uterus (Endometrial cancer)
• Ovarian cancer
• Cancer of the stomach
• Urinary bladder cancer
• Pancreatic cancer
• Brain tumors
• Cancer of the larynx
• Prostate cancer
• Skin cancer (especially Melanoma malignum)

 

as well as Kidney cancer, Liver cancer, Testicular cancer, Thyroid cancer, Metastatic tumors of unknown primary origin etc.

 

"KATRAPS" has not been fully and satisfactory studied in lymphomas, leukaemias, leucosis and ultiple myeloma.

 

 

INDICATIONS & ACTION:

1. "KATRAPS" is highly effective in preventing relapses and metastases formation of malignant tumors after surgical treatment, as well as after radiation therapy and/or chemotherapy. If the patient is receiving chemo- or radiotherapy, then the treatment with KATRAPS must be started at least 2 weeks after the last chemo- or radiotherapy.


2. Treatment with "KATRAPS" is most effective after radical or partial surgical removal of the tumor, but has also demonstrated excellent results in many inoperable tumors.


3. The drug is an optimal alternative for treatment of most type of cancers that are not suitable or impossible for application of surgical operation, radiation therapy and/or chemotherapy.


4. "KATRAPS" has powerful immunostimulating effect, manifested by strong antiviral and antibacterial activity.


5. The drug is used as an immunotherapy of benign tumors, containing glandular tissues (adenomas, glandular polyps) and fibrotic tissues (fibromas, fibroadenomas, fibromyomas) as well as for preventing malignancy of benign tumors.

 

6. Treatment of the mastopathy, endometriosis and myoma of the uterus in women with family history.


7. Treatment of the benign prostatic hyperplasia.


8. Appropriate in those cases where the cancer is not visible but the tumor markers are in higher than normal levels (elevated levels of one or more of the following tumor markers: CA 15-3, CA 19-9, CA 72-4, CA 125, CEA, SCC, PSA, PAP, NSE etc.)

 

 

CONTRAINDICATIONS:

"KATRAPS" does not render any toxic effect in normal cells of the human organism; This vaccine has no mutagenic and teratogenic effect and does not contain any tumor cells.

 

"KATRAPS" is not recommended for use: during pregnancy; during and 3-4 days after acute infectious diseases; during the activation of the chronic diseases; in case of potent allergic reaction to the drug during the previous administration.

 

As a matter of principle "KATRAPS" is not administrated during radiation therapy and/or chemotherapy, but has a powerful effect when applied 10-15 days after their termination.

 

 

SIDE EFFECTS:

Treatment with "KATRAPS" has no side effects, with the exception of mild reversible redness around the application spot in less than 1 % of the cases.

 

The patient should be under doctor's observation during the administration of the drug.

 

 

 

Treatment with "KATRAPS" is administered in three centers (cities) in Bulgaria – Sofia, Plovdiv and Varna (see under “Contacts ”).

 

 

The original package and KATRAPS-vials are shown on the web-page. Any other package or vials are inactive, not authentic, and possibly dangerous.